ProCE Banner Activity

ADAURA: OS Analysis of Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC

Conference Coverage
Slideset

Adjuvant osimertinib showed a significant improvement in OS vs placebo in patients with completely resected, EGFR-mutated early-stage NSCLC.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure